Login
$FEMY
$1.30 +$0.02 (1.56%) After hours

$FEMY SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition
05 Nov 2026 Form 4: Moorhead John Hunnewell Jr, Director

Granted 1,760 Stock Option (Right to Buy)

05 Nov 2026 Form 3: Moorhead John Hunnewell Jr, Director

No securities owned

02 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

ATLANTA – October 30, 2026 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and ...

15 Oct 2026 SCHEDULE 13G
29 Sep 2026 424B3
28 Sep 2026 EFFECT
03 Sep 2026 S-3
31 Aug 2026 SCHEDULE 13G
20 Aug 2026 D
17 Aug 2026 SCHEDULE 13D
14 Aug 2026 10-Q
14 Aug 2026 8-K: Results of Operations and Financial Condition

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval --

14 Aug 2026 SCHEDULE 13G
11 Aug 2026 Form 4: Eichenbaum Kenneth D., Director

Granted 880 Stock Option (Right to Buy)

11 Aug 2026 Form 4: Uzialko Edward R, Director

Granted 880 Stock Option (Right to Buy)

11 Aug 2026 Form 4: Milnes Alistair, Director

Granted 880 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support